Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-09

Clinical Trial Update: ALPPS Combined With Tislelizumab in Liver Malignancy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ALPPS combined with tislelizumab for liver malignant tumors; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Liver Malignant Tumors | Phase 2 | Status: UNKNOWN